Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Older patients with hip fractures recover better if they receive treatment under the supervision of both a surgeon and a specialist in elderly care; are checked to avoid future falls; and are assessed for memory problems.

In the UK, the National Health Service (NHS) has set standards for hip fracture care which identify seven indicators that doctors and healthcare providers are recommended to provide to improve patient outcomes and quality of life.

“These performance indicators are part of the UK NHS Best Practice Tariff (BPT) where providers are reimbursed based on the care delivered in the period following injury,” said Matthew Costa, Professor of Orthopaedic Trauma Surgery at NDORMS.  “But it’s not clear whether the tariff is associated directly with improved patient outcomes or really how much difference each aspect of care makes to a person’s recovery. Through the WHiTE study we could test the seven recommendations to see which had the greatest impact and whether some should be prioritised by hospitals.”

A broken hip is the most common type of injury in older people and can have a devastating impact on pain and mobility, with a long-term reduction in a patient’s quality of life. The World Hip Trauma Evaluation (WHiTE) study was set up in 2014, recruiting patients with hip fractures from 20 NHS hospitals in England to report on health-related quality of life outcomes. Judged to be the most important outcome following this type of injury, Prof. Costa and Prof Griffin’s team could measure the effectiveness of clinical care provided against patients’ quality of life, and from there which elements of best care lead to the most improvement.  

Published in the Bone and Joint Journal, the study looked at more than 8,000 patients aged 60 years and older who had been operated on for a broken hip. Patients received follow up at 4 months to report on their quality of life. The researchers reviewed the treatment patients received against the seven indicators. Around half of patients received all seven recommended aspects of care and they recovered best.

The analysis showed that each of the seven aspects of care contributed to recovery but three stood out as most effective. 

  • Admission under the joint care of a consultant surgeon and a specialist in the care of older people
  • Checks to avoid falls and assess bone health
  • Checks for memory problems before and after surgery

“This study is also the first to show that tariff payments linked to the delivery of recommendations for best care lead to better quality of life for patients”. Professor Costa added: “In an ideal situation patients would receive all seven recommended care treatments and make the best recovery. Where this is not possible we would recommend that hospitals prioritise these three aspects that we have shown to have the greatest impact in improving quality of life following a hip fracture.”  

The WHiTE study is funded by the National Institute for Health Research and the NIHR Oxford Biomedical Research Centre, and supported by the UK Musculoskeletal Trauma Patient and Public Involvement Group.

The WHiTE study is also being used to test new treatments for patients. Current clinical trials include studies looking at surgical devices, new treatments to reduce infection, treatments to reduce confusion after surgery and to speed patients’ recovery.

Similar stories

3,400 different medicines used globally to treat COVID-19

Main Statistics and epidemiology

Insufficient data, and misleading recommendations led to significant early heterogeneity in global COVID-19 patient management, according to recent BMJ study

Clinical trial finds Azithromycin has no benefit against COVID-19

Main OCTRU

A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.

Major ERC funding awarded to Professor Michael Dustin

Awards Kennedy Main

Professor Michael Dustin and an international team of collaborators have been awarded a €10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.

The role of mAbs (neutralising monoclonal antibodies) in the fight against COVID-19

Main Research

Neutralising mAbs, a form of anti-viral medicine, are being explored as an attractive option to treat symptoms of COVID-19 and in some cases prevent infection. But what are the pros and cons of this type of treatment and what should regulators consider before granting approval?

Professor Michael Dustin elected to the National Academy of Sciences

Awards Kennedy Main

Recognised for his outstanding contributions to the field of immunology, Michael becomes the fourth Kennedy professor to be elected to the Academy.

Small mechanical forces in immune cells measured at unprecedented sensitivity

Kennedy Main Research

Oxford researchers have used advanced microscopy techniques to measure previously unseen forces generated by cells during an immune response; a breakthrough for mechanobiology and future advances in health and disease.